CRVS

5.00

11.11% 0.50

Handel nachbörslich: 4.98 -0.02 -0.40%

Corvus Pharmaceuticals Inc (CRVS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$4.50

Offen:

$4.58

24-Stunden-Volumen:

626.94K

Relative Volume:

0.69

Marktkapitalisierung:

$372.57M

Einnahmen:

Nettoeinkommen (Verlust:

$-27.03M

KGV:

-8.9286

EPS:

-0.56

Netto-Cashflow:

$-23.97M

1W Leistung:

+19.90%

1M Leistung:

+20.77%

6M Leistung:

+1.63%

1J Leistung:

+33.16%

1-Tages-Spanne:

$4.5216

$5.05

1-Wochen-Bereich:

$4.051

$5.05

52-Wochen-Spanne:

$2.54

$10.00

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Firmenname

Corvus Pharmaceuticals Inc

Sektor

Healthcare (1161)

Branche

Biotechnology (646)

Telefon

(650) 900-4520

Adresse

863 MITTEN ROAD, BURLINGAME, CA

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-03-25

Neueste SEC-Einreichungen

CRVS's Discussions on Twitter

Vergleichen Sie CRVS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CRVS Corvus Pharmaceuticals Inc	5.00	336.99M	0	-27.03M	-23.97M	-0.56
VRTX Vertex Pharmaceuticals Inc	395.92	99.42B	11.42B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	561.55	58.99B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	432.52	56.35B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	646.60	39.02B	3.05B	1.28B	-614.78M	19.58
ONC Beone Medicines Ltd Adr	307.51	34.25B	3.81B	-644.79M	-669.77M	-6.24

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-01-02	Eingeleitet	H.C. Wainwright	Buy
2023-08-18	Eingeleitet	Oppenheimer	Outperform
2021-12-01	Fortgesetzt	Jefferies	Buy
2021-05-27	Eingeleitet	Cantor Fitzgerald	Overweight
2021-02-10	Herabstufung	Mizuho	Buy → Neutral
2019-09-12	Eingeleitet	Mizuho	Buy
2019-05-29	Eingeleitet	ROTH Capital	Buy
2017-08-24	Hochstufung	Credit Suisse	Underperform → Neutral
2017-05-01	Herabstufung	Credit Suisse	Neutral → Underperform
2016-04-18	Eingeleitet	Credit Suisse	Outperform
2016-04-18	Eingeleitet	Guggenheim	Buy

Alle ansehen

Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten

08:54 AM

Can volume confirm reversal in Corvus Pharmaceuticals Inc.Long Setup & Risk Controlled Daily Trade Plans - Newser

08:54 AM

02:37 AM

What to expect from Corvus Pharmaceuticals Inc. in the next 30 daysJuly 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - Newser

02:37 AM

01:18 AM

Is it time to cut losses on Corvus Pharmaceuticals Inc.July 2025 Short Interest & Capital Efficiency Focused Strategies - Newser

01:18 AM

12:47 PM

Can volume confirm reversal in Corvus Pharmaceuticals Inc. [Rate Cut]Long-Term Growth Plans - Newser

12:47 PM

12:01 PM

Sentiment analysis tools applied to Corvus Pharmaceuticals Inc.Long-Term Safety Investment Analysis Report - Newser

12:01 PM

Aug 12, 2025

Corvus Pharmaceuticals and the 2025 Catalysts for Soquelitinib: A Dual-Target Biotech Play - AInvest

Aug 12, 2025

Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts - Seeking Alpha

Aug 12, 2025

Does Corvus Pharmaceuticals Inc. qualify in momentum factor screeningFree High Accuracy Alerts for ROI Traders - Newser

Aug 12, 2025

Corvus Pharmaceuticals’ Earnings Call Highlights Progress - TipRanks

Aug 12, 2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 12, 2025

Long term hold vs stop loss in Corvus Pharmaceuticals Inc.Watchlist Summary for Active Day Traders - Newser

Aug 12, 2025

What makes Corvus Pharmaceuticals Inc. stock price move sharplyFree Pattern Alert With ROI Driven Strategy - Newser

Aug 12, 2025

How Corvus Pharmaceuticals Inc. stock performs during market volatilityStrong Balance Sheet Candidates - thegnnews.com

Aug 12, 2025

Aug 11, 2025

How to forecast Corvus Pharmaceuticals Inc. trends using time seriesMarket Correction Proof Stock Screening Analysis - Newser

Aug 11, 2025

Advanced analytics toolkit walkthrough for Corvus Pharmaceuticals Inc.Smart Risk Strategy with Entry Optimization - Newser

Aug 11, 2025

Published on: 2025-08-11 02:13:29 - Newser

Aug 11, 2025

Momentum divergence signals in Corvus Pharmaceuticals Inc. chartFree Triple Digit Return Stock Predictions - Newser

Aug 11, 2025

Aug 10, 2025

Is Corvus Pharmaceuticals Inc. stock ready for a breakoutTrend Analysis for Safer Market Entries - Newser

Aug 10, 2025

Price action breakdown for Corvus Pharmaceuticals Inc.Free Daily Growth Stock Pick Reports - Newser

Aug 10, 2025

Is Now a Good Time to Reenter Corvus Pharmaceuticals Inc.Scalable Portfolio Growth Suggestions Released - beatles.ru

Aug 10, 2025

Corvus (CRVS) Q2 Loss Beats Estimates - AOL.com

Aug 10, 2025

Aug 09, 2025

Real time pattern detection on Corvus Pharmaceuticals Inc. stockTechnical Insight Guide for Safer Trades - Newser

Aug 09, 2025

Corvus plans Phase II trial for soquelitinib in atopic dermatitis, targeting 200 patients with 12-week treatment window - MSN

Aug 09, 2025

Traders Watching For Reversal Pattern in Corvus Pharmaceuticals Inc.AI Trading Suggestions With Accuracy Focus Released - metal.it

Aug 09, 2025

Custom strategy builders for tracking Corvus Pharmaceuticals Inc.Free Pattern Detection for Entry Confirmation - Newser

Aug 09, 2025

Aug 08, 2025

What recovery options are there for Corvus Pharmaceuticals Inc.Real Chart Based Opportunity Identification - Newser

Aug 08, 2025

Transcript : Corvus Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener

Aug 08, 2025

Can technical indicators confirm Corvus Pharmaceuticals Inc.’s reversalFree Short Term Setup With Predictive Chart - Newser

Aug 08, 2025

Earnings call transcript: Corvus Pharmaceuticals’ Q2 2025 results show EPS beat By Investing.com - Investing.com South Africa

Aug 08, 2025

Earnings call transcript: Corvus Pharmaceuticals’ Q2 2025 results show EPS beat - Investing.com

Aug 08, 2025